Eisai submits MAA for lecanemab in Great Britain to treat early Alzheimer’s disease
Lecanemab has been designated by the MHRA for the Innovative Licensing and Access Pathway
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.